Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Karyopharm Therapeutics ( (KPTI) ) just unveiled an update.
On January 27, 2025, Karyopharm Therapeutics Inc.’s Compensation Committee approved retention equity awards for key executive officers under its 2022 Equity Incentive Plan, effective February 28, 2025. The awards consist of stock options and restricted stock units designed to incentivize executives, with specific vesting schedules and provisions for accelerated vesting in the event of employment termination following a Change in Control Event.
More about Karyopharm Therapeutics
YTD Price Performance: -18.02%
Average Trading Volume: 910,697
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $83.8M
Find detailed analytics on KPTI stock on TipRanks’ Stock Analysis page.
